Overview

Microbiota Modification for the Treatment of Motor Complication of Parkinson´s Disease

Status:
Completed
Trial end date:
2020-03-30
Target enrollment:
Participant gender:
Summary
In recent years, abnormalities in gut microbiota have been identified in patients with Parkinson´s disease having a possible role in motor manifestations. Among 80 patients with PD, we selected 14 with LID and motor fluctuations with limited response to pharmacological therapy to receive treatment with sodium phosphate enema, oral rifaximin and polyethylene glycol to improve motor complications.
Phase:
Phase 1
Details
Lead Sponsor:
Torre Médica Santé
Treatments:
Rifaximin